$41.56
3.69% day before yesterday
Nasdaq, May 16, 10:00 pm CET
ISIN
NL0011606264
Symbol
MRUS
Sector
Industry

Merus N.V. Stock price

$41.56
-0.35 0.84% 1M
-2.71 6.12% 6M
-0.49 1.17% YTD
-3.46 7.69% 1Y
+25.58 160.08% 3Y
+27.76 201.16% 5Y
+31.52 313.94% 10Y
Nasdaq, Closing price Fri, May 16 2025
+1.48 3.69%
ISIN
NL0011606264
Symbol
MRUS
Sector
Industry

Key metrics

Market capitalization $2.88b
Enterprise Value $2.43b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 44.36
P/S ratio (TTM) P/S ratio 52.56
P/B ratio (TTM) P/B ratio 4.82
Revenue growth (TTM) Revenue growth 42.77%
Revenue (TTM) Revenue $54.73m
EBIT (operating result TTM) EBIT $-301.00m
Free Cash Flow (TTM) Free Cash Flow $-237.08m
Cash position $458.33m
EPS (TTM) EPS $-4.12
P/E forward negative
P/S forward 52.84
EV/Sales forward 44.60
Short interest 8.56%
Show more

Is Merus N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Merus N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Merus N.V. forecast:

18x Buy
100%

Analyst Opinions

18 Analysts have issued a Merus N.V. forecast:

Buy
100%

Financial data from Merus N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
55 55
43% 43%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 84 84
51% 51%
153%
- Research and Development Expense 267 267
85% 85%
488%
-299 -299
82% 82%
-545%
- Depreciation and Amortization 2.45 2.45
4% 4%
4%
EBIT (Operating Income) EBIT -301 -301
81% 81%
-550%
Net Profit -277 -277
85% 85%
-507%

In millions USD.

Don't miss a Thing! We will send you all news about Merus N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Merus N.V. Stock News

Neutral
GlobeNewsWire
3 days ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Neutral
GlobeNewsWire
10 days ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Neutral
GlobeNewsWire
11 days ago
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting
More Merus N.V. News

Company Profile

Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.

Head office Netherlands
CEO Bill Lundberg
Employees 260
Founded 2003
Website www.merus.nl

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today